Kaul C L, Talwalker P K, Grewal R S
Arch Int Pharmacodyn Ther. 1978 Jul;234(1):139-44.
An investigation has been made to see the effect of oral hypoglycemic agants on the blood sugar (BS) and plasma Immuno-Reactive Insulin (IRI) in normal and streptozotocin diabetic rats. Plasma IRI was significantly reduced in a streptozotocin treated diabetic rat 8 weeks after streptozotocin injection. In normal rats oral administration of Sodium tolbutamide (TOL) and Glybenclamide (GLI) produced a significant fall in BS and a concurrent increase in plasma IRI, but phenformin (PHE) was without any effect on both these parameters. Unlike normal rats streptozotocin treated diabetic rats did not show lowering of BS and increase in plasma IRI following TOL and GLI. PHE, however, did produce a significant fall in BS. Oral glucose load did show a typical glucose tolerance curve and insulin release in normal rats. However, in the diabetic rats there was no significant increase in plasma IRI following glucose load. It is therefore concluded that streptozotocin treated diabetic rats differ from the maturity onset diabetic as regards the responses of TOL and GLI are concerned and this animal model can therefore be useful in differentiating the two types of oral hypoglycemic agents.
已开展一项研究，以观察口服降糖药对正常大鼠和链脲佐菌素诱导的糖尿病大鼠的血糖（BS）及血浆免疫反应性胰岛素（IRI）的影响。在注射链脲佐菌素8周后，链脲佐菌素处理的糖尿病大鼠血浆IRI显著降低。在正常大鼠中，口服甲苯磺丁脲（TOL）和格列本脲（GLI）可使血糖显著下降，同时血浆IRI升高，但苯乙双胍（PHE）对这两个参数均无影响。与正常大鼠不同，链脲佐菌素处理的糖尿病大鼠在给予TOL和GLI后，血糖并未降低，血浆IRI也未升高。然而，PHE确实使血糖显著下降。口服葡萄糖负荷试验在正常大鼠中显示出典型的糖耐量曲线和胰岛素释放。然而，糖尿病大鼠在葡萄糖负荷后血浆IRI没有显著增加。因此得出结论，就TOL和GLI的反应而言，链脲佐菌素处理的糖尿病大鼠与成年发病型糖尿病大鼠不同，因此该动物模型可用于区分两种类型的口服降糖药。
